AccuMetab™ Human CYP26B1 Enzyme, Catalytically Active

CAT#: ITS-0426-YL30
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP26B1 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Working in tandem with its family members, CYP26B1 governs the localized degradation of retinoic acid in specific developmental tissues. ADME assays featuring this enzyme are crucial for flagging compounds that may disrupt early embryonic development or trigger retinoid-induced toxicities.
Key Features
Complementary retinoid metabolism pathway; Identifies localized embryonic drug disruption; Ready-to-use recombinant membrane format; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry